Revance Therapeutics Inc (RVNC)

[marthambles]

It's easy to get caught up in the anecdotal stuff out there, but, as Foley said, the therapeutic market is larger than the aesthetic, and it is hard to imagine that the duration benefit of Revance, whether it lasts twice as long or only 1.5 times as long, won't be determinative. Add to that the clear superiority in AEs, and the risk here seems low.

$RVNC Cervical Dystonia results. Low dose looks like a winner. Look at comparative dysphasia rates. pic.twitter.com/BiY4gOOs1e

— David Audet (@DaveAudet) October 14, 2020